Med BioGene Loss Shrinks as It Prepares Lung Test Launch | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene said yesterday that its fiscal-year 2008 net loss declined slightly to C$2.3 million (US$1.9 million), or C$.07 per share, from C$2.4 million, or C$.09 per share.

The Vancouver, BC-based firm had no revenues, as it is gearing up to launch its molecular assay for lung cancer this year. Med BioGene's LungExpress Dx gene expression prognostic assay is being developed for patients with early stage non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.